Harriet Garlant

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey, Sue Ann Costa Clemens, Shabir A. Madhi et al. · The Lancet · 2020 · 5K citations · Full text

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Merryn Voysey, Sue Ann Costa Clemens, Shabir A. Madhi et al. · The Lancet · 2021 · 1.2K citations · Full text

Validation of Differentially Expressed Immune Biomarkers in Latent and Active Tuberculosis by Real-Time PCR

Prem Perumal, Mohamed Bilal Abdullatif, Harriet Garlant et al. · Frontiers in Immunology · 2021 · 27 citations · Full text

World Health Organization, Immunology, Pathology +17

Evaluation of Host Protein Biomarkers by ELISA From Whole Lysed Peripheral Blood for Development of Diagnostic Tests for Active Tuberculosis

Harriet Garlant, Kalaiarasan Ellappan, Matthew Hewitt et al. · Frontiers in Immunology · 2022 · 15 citations · Full text

Point-of-care Testing, Engineering, Elisa From Whole +24

The ‘analysis of gene expression and biomarkers for point-of-care decision support in Sepsis‘ study; temporal clinical parameter analysis and validation of early diagnostic biomarker signatures for severe inflammation andsepsis-SIRS discrimination

Tamás Szakmány, Eleanor Fitzgerald, Harriet Garlant et al. · Frontiers in Immunology · 2024 · 13 citations · Full text